The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents

Published Online:https://doi.org/10.1176/ajp.141.1.20

Of 41 children, adolescents, and young adults who were withdrawn from chronic neuroleptic treatment, 18 developed tardive dyskinesia, withdrawal dyskinesia, nondyskinetic withdrawal symptoms, or transient behavior deterioration. Development of neuroleptic-related problems seemed to be associated with cumulative neuroleptic dose and possibly with the sex of the subject. Only 12 of the 41 subjects required resumption of neuroleptic treatment after a prolonged trial withdrawal period.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.